Annals of Allergy, Asthma & Immunology 1996-05-01

Efficacy of acrivastine plus pseudoephedrine for symptomatic relief of seasonal allergic rhinitis due to mountain cedar.

B O Williams, H Hull, P McSorley, M F Frosolono, R L Sanders

Index: Ann. Allergy Asthma Immunol. 76(5) , 432-8, (1996)

Full Text: HTML

Abstract

Acrivastine is a second-generation H1-antagonist chemically related to triprolidine, but more polar and with less central nervous system penetration than triprolidine.The efficacy of the antihistamine-decongestant combination product (Semprex-D capsules) containing acrivastine 8 mg plus pseudoephedrine HCl 60 mg was evaluated for the treatment of seasonal allergic rhinitis symptoms.A total of 676 patients sensitive to mountain cedar pollen was enrolled into a 6-center, randomized, double-blind, placebo-controlled, parallel, 4-group study designed to compare acrivastine + pseudoephedrine, acrivastine, pseudoephedrine, and placebo. Patients with demonstrable diary symptom scores at baseline took study medication (4 doses/day) and recorded symptom scores twice daily for 2 weeks. The effectiveness of the acrivastine + pseudoephedrine combination was examined relative to the individual components and placebo in terms of changes in diary symptom scores.Over the 2-week period, the combination of acrivastine plus pseudoephedrine was significantly more effective than (1) acrivastine, pseudoephedrine, and placebo (P < .001) for relief of all symptoms; (2) pseudoephedrine (P < .001) for relieving allergy symptoms, ie, running nose, sneezing, itchy nose/throat and tearing; and (3) acrivastine (P < .001) for reducing nasal congestion. Relative to placebo, small increases in adverse experience rates were observed with acrivastine + pseudoephedrine for dry mouth, insomnia, somnolence, and headache.These findings in a large clinical trial demonstrate (1) the efficacy of acrivastine and (2) that each component of the combination of acrivastine 8 mg plus pseudoephedrine HCl 60 mg contributes to the overall efficacy, thereby supporting the conclusion that the combination is rational, safe, and effective for the treatment of allergic rhinitis.


Related Compounds

  • Acrivastine

Related Articles:

Identification of novel functional inhibitors of acid sphingomyelinase.

2011-01-01

[PLoS ONE 6 , e23852, (2011)]

Simultaneous analysis of the H1-antihistamine acrivastine and the decongestant pseudoephedrine hydrochloride by high-performance liquid chromatography.

2005-04-01

[J. Pharm. Biomed. Anal. 37(4) , 663-7, (2005)]

Onset-of-action for antihistamine and decongestant combinations during an outdoor challenge.

2000-04-01

[Ann. Allergy Asthma Immunol. 84(4) , 451-9, (2000)]

Quantification of antihistamine acrivastine in plasma by solid-phase extraction and high-performance liquid chromatography.

2007-01-04

[J. Pharm. Biomed. Anal. 43(1) , 293-7, (2007)]

Evaluation and comparison of five matrix excipients for the controlled release of acrivastine and pseudoephedrine.

2004-01-01

[Drug Dev. Ind. Pharm. 30(10) , 1009-17, (2004)]

More Articles...